We thank the editor for the opportunity to write this commentary on the paper by Jun Shao. The author’s paper gives an excellent review of methods developed for statistical inference when considering covariateadaptive, randomised trial designs. We would like to mention how the results from our paper (Wang et al., 2020) fit into those described by Jun Shao. Our paper focused on stratified permuted block randomisation (Zelen, 1974) and also biased coin randomisation (Efron, 1971), which are categorised as Type 1 randomisation schemes in the author’s paper. According to a survey by Lin et al. (2015) on 224 randomised clinical trials published in leading medical journals in 2014, stratified permuted block randomization was used by 70% of trials. Our goal is to improve precision of statistical inference by combining covariate-adaptive design and covariate adjustment, while providing robustness to model misspecification. In Section 6 of the author’s paper, the same goal was discussed and a linear model of potential outcomes given covariates was considered. Our results generalise those given for linearmodel-based estimators to all M-estimators (under regularity conditions), which covers many estimators used to analyse data from randomised clinical trials. Examples of M-estimators include estimators based on logistic regression (Moore & van der Laan, 2009), inverse probability weighting (Robins et al., 1994), the doubly-robust weighted-least-squares estimator (Robins et al., 2007), the augmented inverse probability weighted estimator (Robins et al., 1994; Scharfstein et al., 1999), and targeted maximum likelihood estimators (TMLE) that converge in 1-step (van der Laan&Gruber, 2012). Our results are able to handle covariate adjustment, various outcome types, repeated measures outcomes and missing outcome data under the missing at random assumption. Using data from three completed trials of substance use disorder treatments, we estimated that the precision gained due to stratified permuted block randomisation and covariate adjustment ranged from 1% to 36%. Another contribution of our paper is to prove the consistency and asymptotic normality of the KaplanMeier estimator under stratified randomization. Its asymptotic variance was also derived. We conjecture that this result can be generalised to cover covariate-adjusted estimators for the survival function, such as estimators by Lu and Tsiatis (2011); Zhang (2015).
[1]
M. J. van der Laan,et al.
Targeted Minimum Loss Based Estimation of Causal Effects of Multiple Time Point Interventions
,
2012,
The international journal of biostatistics.
[2]
B. Efron.
Forcing a sequential experiment to be balanced
,
1971
.
[3]
R. Mojtabai,et al.
Model-Robust Inference for Clinical Trials that Improve Precision by Stratified Randomization and Adjustment for Additional Baseline Variables
,
2019,
1910.13954.
[4]
M. J. van der Laan,et al.
Increasing Power in Randomized Trials with Right Censored Outcomes Through Covariate Adjustment
,
2009,
Journal of biopharmaceutical statistics.
[5]
A. Tsiatis,et al.
Semiparametric estimation of treatment effect with time-lagged response in the presence of informative censoring
,
2011,
Lifetime Data Analysis.
[6]
Zheng Su,et al.
The pursuit of balance: An overview of covariate-adaptive randomization techniques in clinical trials.
,
2015,
Contemporary clinical trials.
[7]
Min Zhang,et al.
Robust methods to improve efficiency and reduce bias in estimating survival curves in randomized clinical trials
,
2015,
Lifetime data analysis.
[8]
J. Robins,et al.
Adjusting for Nonignorable Drop-Out Using Semiparametric Nonresponse Models
,
1999
.
[9]
J. Robins,et al.
Comment: Performance of Double-Robust Estimators When “Inverse Probability” Weights Are Highly Variable
,
2007,
0804.2965.
[10]
J. Robins,et al.
Estimation of Regression Coefficients When Some Regressors are not Always Observed
,
1994
.
[11]
M Zelen,et al.
The randomization and stratification of patients to clinical trials.
,
1974,
Journal of chronic diseases.